about
Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptorsThe synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in ratsThe effect of the antihistaminic drugs on the central action of 5-hydroxytryptophan in miceSome central effects of opipramol given repeatedlyOxaprotiline enantiomers given repeatedly and brain alpha-adrenoceptorsBehavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's diseaseThe anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in ratsEffects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies.Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies.Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression.Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression.Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression.Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice.Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats.Roxindole, a potential antidepressant. I. Effect on the dopamine system.Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats.Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity.Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy.Norepinephrine transporter knockout-induced up-regulation of brain alpha2A/C-adrenergic receptors.Stimulatory effect of antidepressant drug pretreatment on progression of B16F10 melanoma in high-active male and female C57BL/6J mice.Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects.Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test.Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model.Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice.Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex.Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats.Inhibitory effects of amantadine on the production of pro-inflammatory cytokines by stimulated in vitro human blood.Effect of co-administration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test.Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats.Some behavioural effects of antidepressant drugs are time-dependent.Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors.Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats.A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist.Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors.Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors.Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression.
P50
Q28216067-22F419B2-6CD2-4934-BA2C-17890DFFDD14Q28252382-A0945402-FAC0-433B-A103-7CC8113ABC72Q28260590-CFF5496A-5D73-401E-BDDF-4E1550374418Q28329005-1DE3FF5A-8DD0-4F29-B16B-434FDF2DEE35Q28330387-76C3B5EC-7E8F-4290-ABCE-C687FD95660EQ28334363-246DE69F-6426-44D4-8F09-B46116101002Q28369353-CF80784E-35AA-4271-B702-ED56A0FB085DQ28571045-5A218EC3-1AE2-4DBC-8A6B-B59FD878542AQ33196913-0AC67FEB-372B-45F6-913D-2BF0020BD461Q33203093-07B3A0CD-4EF1-4BE9-AFB3-281C52CDC83AQ33211068-CE6E4848-A18E-4141-A2FC-C0079542D0A0Q33211069-55F9AD31-F8E2-4B87-BE76-634026507E89Q33314722-6AAB3119-277D-448B-AD2F-917EDC3B83CAQ34093326-5A1ED6CD-D1B7-416C-9E45-A2BA64F1C2D9Q34290726-104AC42F-3DB0-4BD2-AF42-92D3024407F9Q34397674-A39C8924-1FC6-4C88-B6C4-C660F2CA499BQ34481518-DE00E4FA-0A45-4E82-A62C-D5A7B21AA7E8Q34579438-1BA5A15D-28E3-4E52-BEBC-E7794F69A849Q37306537-C4DCD6B8-A572-4E80-AEC7-3A5499B591FFQ38189554-FA2D28F0-9D3A-4694-BF07-87B198563C1EQ38316708-A0B091A0-85BE-4745-90F0-3F31C2CA0241Q39452204-790FDBBA-4268-468A-A7D8-F85CE3C117BAQ42284615-9FFED447-9132-4A83-951B-5725D2D34CC1Q42465956-506A62EA-3888-45CA-A6F1-44D5F366CF85Q42541141-1D324FE6-DC20-4CCD-9770-22D9B2D4E58DQ42609283-4C14A9F7-264E-43C6-AA42-C8335F9BF081Q42754355-D5CAEFFD-5DEF-4F5E-A1DB-DEBE069C0341Q42754409-B10F2A6D-4C02-4EEB-A46E-07765AFA41A9Q43191747-4C77469F-BF81-4F18-BD8C-43706556141FQ43191760-97E85F62-060E-4810-A94F-799010E9D1ADQ43191771-135CAC5F-E74D-4ECF-BC53-F38D2A0F195AQ43244719-426EED2A-5C59-4E72-8BC7-D927A499583BQ43569258-91864ACD-AB43-4715-9BC5-F75DEA133179Q43951697-C56C0782-4D24-4503-A4E5-3A5C951CCD88Q43976964-5CFFA2AD-FB41-4387-A6B7-873D74610379Q44071645-60401F6E-24D7-4763-B22E-D6546CFD4716Q44200651-1FBF2256-0D96-4846-B68C-2511C51778A1Q44275223-CAB997D7-A482-4C2C-9744-FB1A9536F6DEQ44515585-64C6EE3D-92B1-42D0-A303-F46C8244E010Q44515628-FB41147E-60C2-4494-B121-1E98BBEF3612
P50
description
Forscher
@de
Polish researcher
@en
chercheur
@fr
investigador
@es
polski naukowiec
@pl
taighdeoir Polannach
@ga
wetenschapper
@nl
研究者
@zh
name
Zofia Rogóż
@ast
Zofia Rogóż
@ca
Zofia Rogóż
@cs
Zofia Rogóż
@de
Zofia Rogóż
@en
Zofia Rogóż
@es
Zofia Rogóż
@fr
Zofia Rogóż
@ga
Zofia Rogóż
@gl
Zofia Rogóż
@hr
type
label
Zofia Rogóż
@ast
Zofia Rogóż
@ca
Zofia Rogóż
@cs
Zofia Rogóż
@de
Zofia Rogóż
@en
Zofia Rogóż
@es
Zofia Rogóż
@fr
Zofia Rogóż
@ga
Zofia Rogóż
@gl
Zofia Rogóż
@hr
altLabel
Zofia Maria Rogóż
@pl
Zofia Rogoz
@en
prefLabel
Zofia Rogóż
@ast
Zofia Rogóż
@ca
Zofia Rogóż
@cs
Zofia Rogóż
@de
Zofia Rogóż
@en
Zofia Rogóż
@es
Zofia Rogóż
@fr
Zofia Rogóż
@ga
Zofia Rogóż
@gl
Zofia Rogóż
@hr
P1153
7006864921
P1412
P1559
Zofia Rogóż
@pl
P21
P27
P31
P3124
P496
0000-0002-8538-3594